| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FANCG |
| Uniprot No | O15287 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-622aa |
| 氨基酸序列 | MSRQTTSVGSSCLDLWREKNDRLVRQAKVAQNSGLTLRRQQLAQDALEGLRGLLHSLQGLPAAVPVLPLELTVTCNFIILRASLAQGFTEDQAQDIQRSLERVLETQEQQGPRLEQGLRELWDSVLRASCLLPELLSALHRLVGLQAALWLSADRLGDLALLLETLNGSQSGASKDLLLLLKTWSPPAEELDAPLTLQDAQGLKDVLLTAFAYRQGLQELITGNPDKALSSLHEAASGLCPRPVLVQVYTALGSCHRKMGNPQRALLYLVAALKEGSAWGPPLLEASRLYQQLGDTTAELESLELLVEALNVPCSSKAPQFLIEVELLLPPPDLASPLHCGTQSQTKHILASRCLQTGRAGDAAEHYLDLLALLLDSSEPRFSPPPSPPGPCMPEVFLEAAVALIQAGRAQDALTLCEELLSRTSSLLPKMSRLWEDARKGTKELPYCPLWVSATHLLQGQAWVQLGAQKVAISEFSRCLELLFRATPEEKEQGAAFNCEQGCKSDAALQQLRAAALISRGLEWVASGQDTKALQDFLLSVQMCPGNRDTYFHLLQTLKRLDRRDEATALWWRLEAQTKGSHEDALWSLPLYLESYLSWIRPSDRDAFLEEFRTSLPKSCDL |
| 分子量 | 94.16 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人FANCG蛋白的关键文献概括：
1. **《Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex》**
*作者*：Garcia-Higuera, I., et al. (1999)
*摘要*：研究证实重组表达的人FANCG蛋白与FANCA、FANCC在细胞核内形成复合物，共同参与DNA损伤修复，揭示了其在范可尼贫血症核心复合体中的关键结构作用。
2. **《A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome》**
*作者*：Meetei, A.R., et al. (2003)
*摘要*：通过重组FANCG蛋白的功能分析，发现其与Bloom综合征蛋白BLM相互作用，并参与调控同源重组修复，阐明了范可尼贫血与染色体不稳定综合征间的分子关联。
3. **《Expression of the Fanconi anemia gene FANCG in normal and tumor cells》**
*作者*：Yamashita, T., et al. (1998)
*摘要*：首次报道利用重组技术表达具有功能活性的FANCG蛋白，证明其在正常细胞中可恢复范可尼贫血患者细胞的丝裂霉素C抗性，为基因治疗奠定基础。
(注：部分文献年份较早，可进一步检索近年研究补充，如基因编辑或结构解析方向。)
Recombinant human FANCG protein is a genetically engineered version of the Fanconi anemia group G (FANCG) protein, a critical component of the Fanconi anemia (FA) DNA repair pathway. FANCG, along with other FA core complex proteins (FANCA, FANCC, etc.), facilitates the monoubiquitination of FANCD2 and FANCI, a key step in repairing DNA interstrand crosslinks (ICLs) and maintaining genomic stability. Mutations in FANCG disrupt this pathway, leading to Fanconi anemia, a rare genetic disorder characterized by bone marrow failure, congenital abnormalities, and heightened cancer risk.
The recombinant form of FANCG is typically produced in bacterial or mammalian expression systems, enabling researchers to study its structure, interactions, and functional role in DNA damage response. It serves as a tool to investigate FA pathway mechanisms, model disease-associated mutations, and screen potential therapeutic agents. Additionally, recombinant FANCG is explored in gene therapy strategies, where restoring functional FA proteins could correct hematopoietic defects in patients.
Studies using recombinant FANCG have also clarified its involvement in crosstalk with homologous recombination repair proteins (e.g., BRCA1/2), linking FA pathway dysfunction to cancer predisposition. Despite challenges in achieving stable, bioactive production, recombinant FANCG remains vital for advancing molecular diagnostics and targeted therapies for Fanconi anemia and related malignancies. Its applications extend to understanding chemotherapy sensitivity in FA-deficient cancers, emphasizing its translational relevance.
×
